Insulin deficiency resulted from progressive beta cell failure and insulin resistance in type 2 diabetes requires exogenous insulin therapy, escaping from oral antihyperglycemic agents. Previous data have been suggested that continuous subcutaneous insulin infusion (CSII) does not only have efficacy in glucose control but also restore beta cell failure. The investigators plan to compare the efficacy/safety and beta cell function between insulin pump treatment and the intensification of conventional treatment in patients with uncontrolled type 2 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
140
stop any antihyperglycemic medication and convert to insulin pump
intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
Konkuk University Chungju Hospital
Chungju, South Korea
RECRUITINGchange of HbA1c
Time frame: 24 weeks
changes of body weight
Time frame: 24 weeks
frequency of hypoglycemia
severe hypoglycemia : glucose \<40 mg/dl mild hypoglycemia : glucose 40 - 70 mg/dl
Time frame: 24 weeks
change of beta cell function
insulin secretion-sensitivity index-2 = insulinogenic index x Matsuda index
Time frame: 24 weeks
Percent of patients who reach target goal of HbA1c (<7.0%)
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.